References
- . Seed SM, Dunican KC, Lynch AM, Desilets AR. An update in options for the treatment of pain: a review of new opioid formulations. Hosp Pract (Minneap). 2012;40(1):166–175
- . Rappaport RA. Division Director's Review and Summary Basis for Approval NDA 200533: US Food and Drug Administration; 2011
- . OPANA® ER [package insert]. Chadds Ford, PA: Endo Pharmaceuticals Inc.; 2012
- . Bartholomaeus JH, Arkenau-Marić E, Galia E. Opioid extended-release tablets with improved tamper-resistant properties. Expert Opin Drug Deliv. 2012;9(8):879–891
- . Duragesic® (fentanyl transdermal system) [package insert]. Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2009
- . EXALGO® ER (hydromorphone HCl extended-release tablets) [package insert]. Hazelwood, MO: Mallinckrodt (Covidies); 2010
- . Benedek IH, Jobes J, Xiang Q, Fiske WD. Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. Drug Des Devel Ther. 2011;5:455–463
- . Fiske WD, Jobes J, Xiang Q, Chang SC, Benedek IH. The effects of ethanol on the bioavailability of oxymorphone extended-release tablets and oxymorphone crush-resistant extended-release tablets. J Pain. 2012;13(1):90–99
- . Chou R, Fanciullo GJ, Fine PG, . Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–130
- . Viscusi ER, Pappagallo M. A review of opioids for in-hospital pain management. Hosp Pract (Minneap). 2012;40(1):149–159